Last 11.05 INR
Change Today -0.65 / -5.56%
Volume 3.0
JGPH On Other Exchanges
Symbol
Exchange
Natl India
As of 12:12 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

jagsonpal pharmaceuticals (JGPH) Snapshot

Open
11.00
Previous Close
11.70
Day High
11.05
Day Low
11.00
52 Week High
01/13/14 - 12.85
52 Week Low
08/12/13 - 7.00
Market Cap
289.5M
Average Volume 10 Days
12.9K
EPS TTM
0.70
Shares Outstanding
26.2M
EX-Date
09/25/13
P/E TM
15.8x
Dividend
0.50
Dividend Yield
4.50%
Current Stock Chart for JAGSONPAL PHARMACEUTICALS (JGPH)

Related News

No related news articles were found.

jagsonpal pharmaceuticals (JGPH) Related Businessweek News

No Related Businessweek News Found

jagsonpal pharmaceuticals (JGPH) Details

Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients and formulations worldwide. The company’s active pharmaceutical ingredients (APIs) include allylestrenol, dextropropoxyphene HCL, dextropropoxyphene napsylate, disulfiram, thiopental sodium, thiopental acid, tolnaftate, and sildenafil citrate, as well as metformin HCL, BP, USP, and EP. It offers products for various therapeutic categories, such as anabolic steroids, analgesics, anesthetics, anti-allergic, anti-asthamatics, anti-cholinergic agents, anti-convulsants, anti-diabetics, anti-diarrhoeals, anti-emetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-inflammatory agents, anti-malarials, anti-nauseants, anti-protozoals, anti-pyretic, anti-rheumatic drugs, anti-spasmodic agents, and anti-septic agents. The company also offers anti-tubercular drugs, anti-ulcerants, anxiolytics, cardiovascular drugs, corticosteroids, cough syrups, diuretics, drugs for alcohol dependence, GI anti-infectives, haematinics, imaging agents, laxatives, male/female hormones, multivitamins, nutraceuticals, ophthalmic lubricants, oral rehydrating salts, sedative-hypnotics, softgels, systemic anti-infectives, throat pain spray, tonics, and uterine stimulants. Jagsonpal Pharmaceuticals Limited sells its products under the Lycored, Metadec, Maintane, Metabol, Doxypal DR, Parvon, and Indocap SR names. The company was founded in 1964 and is based in New Delhi, India.

Founded in 1964

jagsonpal pharmaceuticals (JGPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jagsonpal pharmaceuticals (JGPH) Key Developments

JAGSONPAL Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

JAGSONPAL Pharmaceuticals Ltd. announced unaudited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported net sales of INR 377.016 million against INR 493.212 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 22.562 million against INR 28.713 million a year ago. Profit from ordinary activities before tax was INR 11.740 million against INR 15.540 million a year ago. Net profit for the period was INR 8.892 million against INR 10.840 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 0.34 against INR 0.41 a year ago. For the nine months, the company reported net sales of INR 1,125.701 million against INR 1,283.314 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 48.288 million against INR 61.833 million a year ago. Profit from ordinary activities before tax was INR 12.785 million against INR 24.540 million a year ago. Net profit for the period was INR 8.987 million against INR 15.040 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 0.34 against INR 0.57 a year ago.

JAGSONPAL Pharmaceuticals Ltd, Board Meeting, Feb 13, 2014

JAGSONPAL Pharmaceuticals Ltd, Board Meeting, Feb 13, 2014. Agenda: To consider the quarterly results.

JAGSONPAL Pharmaceuticals Ltd Announces Unaudited Earnings Results for the Second Quarter and Half Year Ended September 30, 2013

JAGSONPAL Pharmaceuticals Ltd. announced unaudited earnings results for the second quarter and half year ended September 30, 2013. For the quarter, the company reported net sales of INR 367.897 million against INR 417.833 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 12.142 million against INR 20.036 million a year ago. Profit from ordinary activities before tax was INR 0.959 million against INR 7.494 million a year ago. Net profit for the period was INR 0.059 million against INR 4.194 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 0.00 against INR 0.16 a year ago. For the half year, the company reported net sales of INR 748.685 million against INR 790.102 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 25.726 million against INR 33.120 million a year ago. Profit from ordinary activities before tax was INR 1.045 million against INR 9.0 million a year ago. Net profit for the period was INR 0.095 million against INR 4.20 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 0.00 against INR 0.16 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JGPH:IN 11.05 INR -0.65

JGPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JGPH.
View Industry Companies
 

Industry Analysis

JGPH

Industry Average

Valuation JGPH Industry Range
Price/Earnings 24.7x
Price/Sales 0.2x
Price/Book -- Not Meaningful
Price/Cash Flow 7.5x
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAGSONPAL PHARMACEUTICALS, please visit www.jagsonpal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.